Patients with a confirmed diagnosis of: 
1. Stage 4 colon cancer either s/p metastasectomy or post-initial chemotherapy or maintenance "standard of care", either involving 5-fluorouracil/leucovorin (5-FU/LV) alone or continual bevacizumab alone. Patients in maintenance cohort must have had 2 consecutive CT scans showing stable disease and not be experiencing significant prior treatment-related toxicity above Grade 1. 
2. Pancreas cancer, either s/p resection and adjuvant chemotherapy or locally advanced pancreas cancer s/p chemotherapy and radiation. Initial chemotherapy or radiation therapy may have been stopped between 2 weeks and 2 months prior to study start, and patients must have recovered from prior treatment related toxicity to grade 1 or less. 
Prior surgery, including tumor resection or metastasectomy must have been performed at least 4 weeks prior to study enrollment. 
No concomitant anti-cancer treatment is allowed 
Age >/= 18 years 
Performance status of 0-1 
Adequate hepatic, bone marrow, and renal function 
Partial thromboplastin time (PTT) must be </= 1.5 x upper normal limit of institution's normal range and INR (International Normalized Ratio) < 1.5. 
Life expectancy >/= 4 months for maintenance cohorts and >/= 6 months for adjuvant cohorts 
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and must not be lactating. 
Subject is capable of understanding and complying with protocol demands and able to sign and date the informed consent 

NCT01888965_inc_T2
Condition
colon cancer
NCT01888965_inc_T3
Qualifier
Stage 4
NCT01888965_inc_T4
Condition
s/p metastasectomy
NCT01888965_inc_T5
Procedure
metastasectomy
NCT01888965_inc_T6
Condition
post-initial chemotherapy
NCT01888965_inc_T7
Procedure
chemotherapy
NCT01888965_inc_T8
Drug
5-fluorouracil/leucovorin (5-FU/LV)
NCT01888965_inc_T9
Drug
bevacizumab
NCT01888965_inc_T10
Scope
5-fluorouracil/leucovorin (5-FU/LV) alone or continual bevacizumab
NCT01888965_inc_T11
Procedure
maintenance "standard of care"
NCT01888965_inc_T13
Multiplier
2
NCT01888965_inc_T14
Procedure
CT scans
NCT01888965_inc_T15
Qualifier
stable
NCT01888965_inc_T16
Condition
disease
NCT01888965_inc_T18
Condition
treatment-related toxicity
NCT01888965_inc_T19
Temporal
prior
NCT01888965_inc_T20
Negation
not
NCT01888965_inc_T21
Condition
Pancreas cancer
NCT01888965_inc_T22
Condition
s/p resection
NCT01888965_inc_T23
Procedure
resection
NCT01888965_inc_T24
Condition
s/p adjuvant chemotherapy
NCT01888965_inc_T25
Procedure
adjuvant chemotherapy
NCT01888965_inc_T26
Condition
pancreas cancer
NCT01888965_inc_T27
Qualifier
locally advanced
NCT01888965_inc_T28
Condition
s/p chemotherapy
NCT01888965_inc_T29
Procedure
chemotherapy
NCT01888965_inc_T30
Condition
s/p radiation
NCT01888965_inc_T31
Procedure
radiation
NCT01888965_inc_T32
Procedure
chemotherapy
NCT01888965_inc_T33
Procedure
radiation therapy
NCT01888965_inc_T34
Temporal
between 2 weeks and 2 months prior to study start
NCT01888965_inc_T35
Reference_point
study start
NCT01888965_inc_T36
Condition
recovered from prior treatment
NCT01888965_inc_T37
Procedure
treatment
NCT01888965_inc_T38
Temporal
prior
NCT01888965_inc_T39
Scope
s/p resection and adjuvant chemotherapy
NCT01888965_inc_T40
Scope
locally advanced pancreas cancer s/p chemotherapy and radiation
NCT01888965_inc_T41
Observation
may have been stopped
NCT01888965_inc_T42
Scope
chemotherapy or radiation therapy
NCT01888965_inc_T43
Procedure
surgery
NCT01888965_inc_T44
Temporal
Prior
NCT01888965_inc_T45
Procedure
metastasectomy
NCT01888965_inc_T46
Procedure
tumor resection
NCT01888965_inc_T47
Temporal
at least 4 weeks prior to study enrollment
NCT01888965_inc_T48
Reference_point
study enrollment
NCT01888965_inc_T49
Scope
tumor resection or metastasectomy
NCT01888965_inc_T52
Person
Age
NCT01888965_inc_T53
Value
>/= 18 years
NCT01888965_inc_T54
Measurement
Performance status
NCT01888965_inc_T55
Value
0-1
NCT01888965_inc_T56
Measurement
renal function
NCT01888965_inc_T57
Measurement
bone marrow function
NCT01888965_inc_T58
Measurement
function hepatic
NCT01888965_inc_T59
Value
Adequate
NCT01888965_inc_T60
Measurement
Partial thromboplastin time (PTT)
NCT01888965_inc_T61
Value
</= 1.5 x upper normal limit
NCT01888965_inc_T62
Measurement
INR (International Normalized Ratio)
NCT01888965_inc_T63
Value
< 1.5
NCT01888965_inc_T64
Observation
Life expectancy
NCT01888965_inc_T65
Value
>/= 4 months
NCT01888965_inc_T67
Observation
maintenance cohorts
NCT01888965_inc_T68
Value
>/= 6 months
NCT01888965_inc_T69
Observation
adjuvant cohorts
NCT01888965_inc_T70
Scope
>/= 4 months for maintenance cohorts and >/= 6 months for adjuvant cohorts
NCT01888965_inc_T71
Condition
childbearing potential
NCT01888965_inc_T72
Person
Women
NCT01888965_inc_T73
Measurement
serum pregnancy test
NCT01888965_inc_T74
Value
negative
NCT01888965_inc_T75
Temporal
within 14 days prior to initiation of treatment
NCT01888965_inc_T76
Reference_point
initiation of treatment
NCT01888965_inc_T77
Condition
lactating
NCT01888965_inc_T78
Negation
not
NCT01888965_inc_T79
Scope
Women of childbearing potential